首页> 外文OA文献 >791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

【2h】

791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

机译：791复发或难治经典霍奇金淋巴瘤（CHL）患者中的抗程序化细胞死亡-1（PD-1）抗体Penpulimab的II期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Yuqin Song; Keshu Zhou; Chuan Jin; Zhengzi Qian; Ming Hou; Lei Fan; Fei Li; Kaiyang Ding; Hui Zhou; Xiaoling Li; Bing Chen; Xiuhua Sun; Xianmin Song; Ming Jiang; Qingyuan Zhang; Lihong Liu; Guohua Yu; Yu Hu; Zheng Zhao; Ligen Liu; Hongwei Xue; Jun Luo; Bai He; Xiaoping Jin; Maxwell Wang; Baiyong Li; Yu Xia; Jun Zhu;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 复发难治T细胞非霍奇金淋巴瘤患者的疗效及预后分析 [J] . 高岩, 黄慧强, 林旭滨, 癌症（英文版） . 2007,第008期
2. 复发性晚期滤泡性淋巴瘤的IDEC-C2B8(利妥希玛)抗CD20抗体治疗:德国低度恶性淋巴瘤研究组Ⅱ期研究结果 [J] . 李登举, 唐锦治中德临床肿瘤学杂志（英文版） . 2001,第004期
3. 791?A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL) [J] . Yuqin Song, Keshu Zhou, Chuan Jin, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：791？在复发或难治经典霍奇金淋巴瘤（CHL）患者中，对抗程序化细胞死亡-1（PD-1）抗体Penpulimab的II期研究
4. Allogeneic Stem Cell Transplantation (Allo-SCT) after Treatment with Programmed Cell Death-1 (PD-1) Checkpoint Inhibitors for Relapsed/Refractory Classic Hodgkin Lymphoma (R/R cHL) Is Associated with an Unprecedented Low Relapse Rate [J] . Santoro Armando, Castagna Luca, Magagnoli Massimo, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：用编程的细胞死亡-1（PD-1）检查后的同种异体干细胞移植（Allo-SCT）用于复发/难治性经典霍格金淋巴瘤（R / R CHL）的检查点抑制剂与前所未有的低复发率相关
5. 804?A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy [J] . Xiaozhong Chen, Wei Wang, Qingfeng Zou, Journal for ImmunoTherapy of Cancer . 2020,第Suppla3期

机译：804？在两次或更多种化疗后进行的转移性鼻咽癌（NPC）患者中，对抗程序化细胞死亡-1（PD-1）抗体Penpulimab的II期研究
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Phase II study of pembrolizumab (MK-3475) for relapsed/refractory classical Hodgkin Lymphoma (r/r cHL): keynote-087 [O] . Robert Chen, Phillippe Armand, Michelle A Fanale, 2015

机译：派姆单抗（MK-3475）用于复发/难治性经典霍奇金淋巴瘤（r / r cHL）的II期研究：主题演讲087
8. 895P Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin’s lymphoma [O] . Y-K. Shi, Y. Song, Y. Qin, 2020

机译：895P期I型研究结果II型甘油型抗CD20单克隆抗体MIL62中的复发/难治性CD20阳性B细胞非霍奇金淋巴瘤

791 A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with relapsed or refractory classic hodgkin lymphoma (cHL)

著录项

引文网络

相似文献

相关主题

期刊订阅